Aura Biosciences

AURA · NASDAQ

$6.56+$0.27 (+4.29%)TodayMarket closed ·
Prev close $6.29

Latest news

  • Press releaseGlobe Newswire

    Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseGlobe Newswire

    Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

  • NewsAvi Kapoor

    Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

  • Press releaseGlobe Newswire

    Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

  • News

    Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027

  • Press releaseGlobe Newswire

    Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

  • Press releaseGlobe Newswire

    Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

  • NewsAvi Kapoor

    Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday

  • NewsAvi Kapoor

    Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

  • Press releaseGlobe Newswire

    Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

  • Press releaseGlobe Newswire

    Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

  • News

    12 Health Care Stocks Moving In Monday's Pre-Market Session

  • NewsAvi Kapoor

    BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

  • Press releaseGlobe Newswire

    Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

  • NewsAvi Kapoor

    Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

  • NewsRishabh Mishra

    US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert

  • NewsAvi Kapoor

    Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket

  • NewsVandana Singh

    Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.